{"id":14622,"date":"2011-10-10T08:00:42","date_gmt":"2011-10-10T12:00:42","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=14622"},"modified":"2011-10-10T00:36:22","modified_gmt":"2011-10-10T04:36:22","slug":"paper-churning-why","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2011\/10\/10\/paper-churning-why\/","title":{"rendered":"paper churning. why?…"},"content":{"rendered":"
\n
\n
Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial<\/font><\/strong><\/u><\/a>
by Ira M. Lesser, M.D., Sidney Zisook, M.D., Bradley N. Gaynes, M.D., M.P.H., Stephen R. Wisniewski, Ph.D., James F. Luther, M.A., Maurizio Fava, M.D., Ahsan Khan, M.D., Patrick McGrath, M.D., Diane Warden, Ph.D., A. John Rush, M.D. and Madhukar Trivedi, M.D.<\/sup>
Psychiatric Services<\/font><\/strong>  2011 62:1167-1179.<\/div>\n

<\/p>\n

Methods<\/font><\/strong><\/u>: This single-blind, seven-month prospective, randomized trial enrolled 352 non-Hispanic white [59%], 169 black [28%], and 79 white Hispanic [13%] participants from six primary and nine psychiatric care U.S. sites. Patients had nonpsychotic chronic or recurrent major depressive disorder [or both] of at least moderate severity. Escitalopram plus placebo, bupropion sustained-release plus escitalopram, or venlafaxine extended-release plus mirtazapine were delivered according to measurement-based care. The primary outcome was remission [last two consecutive 16-item Quick Inventory of Depressive Symptomatology-Self-Report ratings <8 and <6]; secondary outcomes included side effects, adverse events, quality of life, function, and attrition.
Conclusions<\/font><\/strong><\/u>: Despite differences in sociodemographic characteristics and comorbidities, when measurement-based care was used, members of different minority groups had similar outcomes when treated with one antidepressant or a combination of two antidepressants. Black participants had the highest attrition rate, an important issue to address in clinical care.
<\/sup><\/p>\n
…The authors also acknowledge the editorial support of Jon Kilner, M.S., M.A.<\/font><\/strong><\/sup><\/div>\n<\/div>\n<\/blockquote>\n
In the last post, I was reminded of the glut of STAR*D<\/font><\/strong> articles that just kept<\/strike> keep coming. One might have thought they would go light on a study so absolutely negative as CO-MED<\/font><\/strong>, but they’ve squeezed out a total of four extra meaningless papers beyond the negative study report so far: <\/div>\n